Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors

Caroline E. Porter, Amanda Rosewell Shaw, Youngrock Jung, Tiffany Yip, Patricia D. Castro, Vlad C. Sandulache, Andrew Sikora, Stephen Gottschalk, Michael M. Ittman, Malcolm Brenner, Masataka Suzuki

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

To enable HER2.CAR T cells to target two tumor antigens through both CAR and native TCR, Porter et al. developed a binary oncolytic-helper adenovirus expressing an engager molecule (BiTE), IL-12, and PD-L1 antibody. This combination therapy significantly improved tumor control and survival in models of HER2-positive and HER-negative cancer.

Original languageEnglish (US)
Pages (from-to)1251-1262
Number of pages12
JournalMolecular Therapy
Volume28
Issue number5
DOIs
StatePublished - May 6 2020

Keywords

  • oncolytic viro-immunotherapy, CAR T cell, BiTE molecule, cytokine, checkpoint inhibitor, CD44 variant 6

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors'. Together they form a unique fingerprint.

Cite this